Skip to content
Study details
Enrolling now

A Study of JNJ-89402638 for Metastatic Colorectal Cancer

Janssen Research & Development, LLC
NCT IDNCT06663319ClinicalTrials.gov data as of Apr 2026
Phase

Phase 1

Target enrollment

170

Study length

about 3.8 years

Ages

18+

Locations

5 sites in CO, FL, IN +2

About this study

This trial is testing a treatment called JNJ-89402638 in people with advanced colorectal cancer that cannot be surgically removed. The goal is to find the best dose of this medication and see if it's safe at that dose.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Take JNJ-89402638
PhasePhase 1
DrugBevacizumab
Routeinfusion
Primary goalPart 1 and Part 2: Number of Participants with Adverse Events (AEs) by Severity

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low9%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Drug classes

bevacizumab

Drug routes

infusion

Endpoints

Primary: Part 1 and Part 2: Number of Participants with Adverse Events (AEs) by Severity, Part 1: Number of Participants with Dose-Limiting Toxicity (DLT)

Secondary: Part 1 and Part 2: Area Under the Serum Concentration-time Curve (AUC) of JNJ-89402638, Part 1 and Part 2: Complete Response (CR), Part 1 and Part 2: Duration of Response (DOR), Part 1 and Part 2: Maximum Serum Concentration (Cmax) of JNJ-89402638, Part 1 and Part 2: Overall Response (OR), Part 1 and Part 2: Time to Reach Maximum Observed Serum Concentration (Tmax) of JNJ-89402638

Body systems

Oncology